PFF Position Statements
The position statements are produced by a group of clinicians in the field utilizing published data and expert opinion. The statements are intended to be informational in nature and meant to complement published guidelines and do not replace medical judgment on an individual basis.
Non-prescription Supplemental Oxygen
The PFF recommends that patients should only use FDA approved oxygen delivery devices as prescribed by their doctor and should not purchase an oxygen supply device without a prescription. Non-FDA approved oxygen delivery systems may not reliably deliver oxygen.
Updated: March 2023
Palliative care relieves symptoms and suffering and promotes the best possible quality of life for patients and their families.
Genetic Testing in Pulmonary Fibrosis
Publish Date: April 2020
A diagnosis of FPF should be suspected when a PF patient has at least one other closely related relatives affected by pulmonary fibrosis. These patients should be considered for genetic counseling and testing.
Surgical Lung Biopsy
Publish Date: August 2019
A surgical lung biopsy (SLB) is an important diagnostic procedure in the evaluation of patients with fibrotic interstitial lung disease (fILD).
Publish Date: January 2022
An update of stem cell/cell based therapies for pulmonary fibrosis beyond the context of clinical trials. A word of caution by the Medical Advisory Board of the Pulmonary Fibrosis Foundation
High-Resolution Computed Tomography
Publish Date: June 2018
Recommended protocol for HRCT for imaging those with suspected interstitial lung disease.